MARKET

CERS

CERS

Cerus
NASDAQ
2.190
+0.030
+1.39%
After Hours: 2.260 +0.07 +3.20% 19:47 12/17 EST
OPEN
2.185
PREV CLOSE
2.160
HIGH
2.260
LOW
2.120
VOLUME
3.01M
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
1.120
MARKET CAP
420.67M
P/E (TTM)
-25.8255
1D
5D
1M
3M
1Y
5Y
1D
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 1d ago
Weekly Report: what happened at CERS last week (1208-1212)?
Weekly Report · 2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying
NASDAQ · 6d ago
*Cerus: Will Partner With BCA to Drive Expanded Access to Pathogen Reduction Technology for Platelets, Plasma and Pathogen Reduced Cryoprecipitated Fibrinogen Complex >CERS
Dow Jones · 12/10 21:39
*Cerus Corp: Announces Group Purchasing Agreement With Blood Centers of Amer
Dow Jones · 12/10 21:39
Cerus To Partner With Blood Centers Of America To Drive Expanded Access To Pathogen Reduction Technology For INTERCEPT Fibrinogen Complex Across Blood Center Membership
Benzinga · 12/10 21:23
Cerus announces group purchasing pact with Blood Centers of America
TipRanks · 12/10 21:20
More
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Webull offers Cerus Corp stock information, including NASDAQ: CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.